Skip to search boxSkip to navigationSkip to main content

Co-Enzyme Q10 to treat neurological disorders: Basic mechanisms, clinical outcomes, and future research direction

*Corresponding author for this work
  • Mansoura University
    ,
  • NCI
    ,
  • Universidade Salgado de Oliveira
    ,
  • Universidade Federal de Uberlândia
    ,
  • Universidade Federal do Rio de Janeiro
    ,
  • Universidad Central de Chile
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 641-644 (4 pages)

Journal (Volume, Issue Number)

CNS and Neurological Disorders - Drug Targets (Volume 12, Issue 5)

Publication milestones

  • Published - 28/08/2013

Publication status

Published - 28/08/2013

ISSN

1871-5273

Publication IDs

  • Scopus: 84882763118

Abstract

Coenzyme Q10 (CoQ10) is critical for the cell power supply in mitochondria. CoQ10 shuttles electrons from complexes I and II to complex III, and can be anti-oxdiative. Neurons require high energy for synaptic transmission and therefore the mitochondria dysfunction often leads to severe neuronal degeneration, as observed in many neurological disorders. CoQ10 supplementation has been widely used to treat aging, stroke, neuromuscular diseases, Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, autosomal recessive cerebellar ataxias, Huntington's disease and amyotrophic lateral sclerosis. Here we discuss a large number of preclinical and clinical trials for CoQ10 to elucidate the mechanisms underlying CoQ10 therapy. The rational applications as a therapeutic agent in neurological disorders are discussed.